Shares of Ventyx Biosciences, Inc. (VTYX) surged more than 75% to $ 41,29 after Oppenheimer kept the stock's Outperform rating and increased its price target from $40 to $ 65..
Trooper Trading Momentum scanner
The momentum zone alerts, pinged us that VTYX was in its highs and a possible runner. Our FREE to use stock scanner, with the different pre-defined alert types, can be here: https://app.trooper.trading/.
Successful VTYX trades
After having received the alert and drawing our support and resistance lines, we decided to do enter a trade. With success!
The price was moving up rather aggressively. Since I prefer 'slow moving prices' and this one was rather volatile, I left the trade manually when I felt a resistance. The $40 limit was such a resistance and I sold without a doubt.
Afterwards, we saw the price breaking the $40 and moving up to $41,29. However, we don't hit for the home-runs. ;)
Glad with the winning trade resulting in a 1% gain of my total account capital.
Check it out for yourself below. Tips and feedback are, as always, welcome!
Ventyx Biosciences
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, Crohn's disease, and lupus. It also develops VTX002, an oral sphingosine 1 phosphate receptor 1 modulator that is in phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor for the treatment of systemic inflammatory diseases, such as cardiovascular, hepatic, renal, and rheumatologic diseases which is in phase I clinical trials. In addition, the company develops CNS-penetrant NLRP3 inhibitors for the treatment of Alzheimer disease, Parkinson disease, amyotrophic lateral sclerosis, and multiple sclerosis. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California. (Source Yahoo Finance)
Kommentarer